Abstract
Introduction
Type 2 diabetes mellitus (DM), is a multifactorial, chronic adult-onset condition characterized by insufficient insulin secretion and inefficient insulin action, thus 2 DM, with a total of 1.5 million diagnosed individuals [3] .
Several studies have shown that individuals with a decreased antioxidant capacity are at higher risk of developing DM [4, 5] .
Glutathione S-transferases (GSTs) are the primary cellular defense mechanism against reactive oxygen species as phase II detoxifying isoenzymes known to metabolize a variety of electrophilic compounds, including drugs, carcinogens, toxins and ROS generated DNA products. Eight members of soluble GSTs have been identified in humans, named Mu (M), Kappa (K), Alpha (A), Pi, accounting for 4% of the total cytosolic proteins in the liver [6, 7] . Among the numerous candidate genes involved in DM pathogenesis, the GST isoemzyme family has been intensely studied in all types of diabetes due to its potential modulating roles in individual susceptibility to multifactorial, environmentally induced disorders. Among these, glutathione S transferase isoemzyme type M1 (GSTM1) and glutathione S transferase isoemzyme type T1 (GSTT1) genes are extremely polymorphic in humans and the null genotypes resulting from loss of function mutations are accompanied by lack of enzyme activity [8, 9] .
Several studies investigated the possible relation between GSTM1 and GSTT1 null alleles and T2DM; Turkish, North Indian and Southern Iran populations highlighted an association between GSTM1 deletion and DM whereas Egyptian, Chinese, and Brazilian population reported significant association between GSTM1/GSTT1 null genotypes and type 2 diabetes [10] [11] [12] [13] [14] [15] .
In a recent studies and meta-analysis, GSTM1 and GSTT1 null genotypes have been associated with a higher risk of developing DM in Japanese and South Indian and African population [16] [17] [18] [19] .
The aim of the present study is to determine the possible association between the incidence of type 2 DM and gene polymorphisms of glutathione S-transferase GSTM1 and GSTT1 in a population group of Northern Romania and to see if GSTM1/GSTT1 null genotypes may be considered a genetic risk factor for DM.
Materials and methods

Patients and controls
This is a molecular epidemiologic case-controlled study, in which we included a group of 106 patients diagnosed with type 2 DM (patients of Diabetes Clinic of the Emergency County Hospital of Cluj) and 124 healthy controls (non-diabetic patients recruited from the Internal Medicine Department of the Emergency County Hospital Cluj). In order to obtain homogeneity regarding proportion and the range of ages and gender we selected and approximate similar age/gender matched subject for each of the subject, respectively control groups.
Ethical issues. The current study was approved by the Local Ethics Committee. The study was conducted according to the Ethical Principles for Medical Research Involving Human Subjects of the World Medical Association Declaration of Helsinki. Written informed consent was obtained from each participant after a brief and clarified explanation about the survey. Bid HK et al.) [20] Genotyping for GSTM1 and GSTT1 alleles was carried out using a Multiplex PCR protocol (18) .
Molecular analysis of GSTM1 and GSTT1 genes (Protocol adapted after
A total volume of 25 µl reaction commercial mixture containing 12.5 µl 2xPCR Master Mix (Thermo Fischer Scientific Inc., MA, USA), 25 µl of free nuclease water and 10 µm of each specific forward and reverse primers.
GSTM1 and GSTT1 null allele identification required the use of 3 pairs of primers
( 5 ' -G A A C T C C C T G A A A A G C TA A A G C -3 ' ; 5'-GTTGGGCTCAAATATAGGGTGG-3' and 5 ' -T T C C T TA C T G G T C C T C A C AT C T C -3 ' ; 5'-TCACCGGATCATGGCCAGCA-3' (Eurogentec Bg.)
As an internal standard amplification marker, β Globin was co-amplified using another pair of primers (5'-CAACTTCATCCACGTTCACC-3' and 5'-GAAGAGCCAAGGACAGGTAC-3' (Eurogentec, Bg.) Termocycling conditions consisted of an initial denaturation at 94°C for 5 minutes followed by 35 repetitive cycles each with a DNA denaturation at 94°C for 1 minute, primers annealing for 1 minute at 58°C, polymerization at 72°C for 1 minute and a final elongation for 10 minutes at 72°C. (Mastercycler Gradient®, Eppendorf, Germany). The resulted amplified DNA products were then analyzed by agarose 2% gel electrophoresis (MetaPhor® Agarose, Cambrex Bio Science Inc.), obtaining 3 different fragments, one of 215 bp (for GSTM1gene), one of 480 bp (for GSTT1 gene) and a 268 bp fragment (for the β Globin gene control fragment). The absence of the amplification specific products revealed the presence of the mutant, null genotypes. We must specify that the current protocol easily identifies the GSTT1 and GSTM1 homozygous null genotypes but cannot distinguish between GSTM1 and GSTT1 homozygous and heterozygous positive genotypes (Fig. 1) .
Statistical analysis
Statistical analysis used a licensed Graphpad software. Odds ration (OR) with 95% confidence limits calculated by logistic regression. GSTM1 and GSTT1 genotypes were classified as either null (homozygous deletion) or wild type, non-deleted. For a more accurate risk evaluation, Z and P values were also calculated.
Results
A total of 106 subjects with DM and 124 controls were investigated in the current study. The proportions of genders in case and control group proved not significantly different (Z-statistics=1.515, p-value=0.1298). The mean age of subjects with DM was 64.43±9.72 years old and
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Statistical analysis did not reveal an increased frequency of GSTM1, respectively GSTT1 null genotypes (mutant alleles) in the DM group compared to controls (p=0.171, OR=1.444 CI=0.852-2.447; p=0.647, OR=0.854, CI=0.436-1.673). Nevertheless, the combined GSTM1/ GSTT1 null genotypes were statistically significant higher in DM patients compared to control subjects (p=0.0021, OR=0.313, CI=0.149-0.655) ( Table II) .
The genotype-gender associated statistical data revealed a higher frequency for the combined GSTM1/ GSTT1 null genotypes in women with diabetes compared to male subjects (p=0.037, OR=0.245, CI=0.065-0.918). There was also an increased frequency of the GSTT1 null genotypes in males diabetics compared to controls (p=0.021, OR=0.343. CI=0.138-0.851).
In cases of the GSTM1-null genotype and combined GSTM1/GSTT1 null genotypes there were higher levels of HbA1c compared to GSTM1/GSTT1 positive genotypes. (p=0.028, OR=0.271; CI=0.124-0.742) (Table III) .
Discussion
Type 2 DM is one of the most common chronic diseases in modern countries and represents a health problem and a major epidemic during the past decades. [21, 22] Many studies have evaluated the association between GST polymorphisms and to our knowledge this is the first study evaluating the association of GSTM1 and GSTT1 null genotypes and type 2 DM in the Romanian population.
We hypothesized that the genetic variability of GST detoxifying enzymes regulating oxidative stress could be involved in development of DM.
The GSTT1 and GSTM1 combined deletion polymorphisms (null alleles), which associate abolished [23] .
Our results come in agreement with other studies that highlighted the same results, placing combined GSTM1/GSTT1 deleted genotypes among the inheritable risk factor for DM development [19] [20] [21] [22] 24, 25] .
Another finding of the current study is that a genotype-gender statistical association revealed a higher frequency for the combined GSTM1/GSTT1 null genotypes in women with diabetes compared to male subjects. Also, there was an increased frequency of the GSTT1 null genotypes in males diabetics compared to controls. There are only a few studies that evaluate the GST mutant genotype -gender in DM.
In conclusion, GSTM1 and GSTT1 mutant variants individually are not associated with DM; however, combined GSTM1/GSTT1 null genotypes could represent independent risk factor for DM. Additionally, GSTT1 null genotypes and combined GSTM1/GSTT1 null genotypes could be considered genetic risk factor in type 2 DM in males and women respectively. Testing for genetic markers in genes encoding antioxidant enzymes like GSTs, either individually or in combination with other polymorphic genetic variants possibly involved in DM pathogen, could be added to a genetic panel for identifying patients at higher risk for developing diabetes in clinical practice.
Our study has a series of limitations. First, the small number of subjects represents a major limitation, therefore the resulting data of the study may not be representative for the general population. For this purpose, future studies with larger number of subjects with different population ethnicity are required and a longitudinal design is also necessary. Another limitation is the lack of correlation with clinical parameters associated with type 2 DM (lifestyle, medication, associated pathology, complications, etc.).
